Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.640 -0.050 (-0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,150,475
Open 9.690
Bid (Size) 9.610 (1)
Ask (Size) 9.690 (10)
Prev. Close 9.690
Today's Range 9.565 - 9.730
52wk Range 8.420 - 12.40
Shares Outstanding 1,212,301,241
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Viatris Inc.are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7." 
Via Benzinga

Performance

YTD
-15.29%
-15.29%
1 Month
-11.96%
-11.96%
3 Month
-2.13%
-2.13%
6 Month
+1.80%
+1.80%
1 Year
+10.93%
+10.93%

More News

Read More
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
Viatris Stock: Bear vs. Bull
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Where Will Viatris Be in 5 Years?
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Via The Motley Fool
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is Viatris Stock Good for Dividend Income?
Via The Motley Fool
A Preview Of Viatris's Earnings
Via Benzinga
Viatris Stock: Bull vs. Bear
Via The Motley Fool
Daily Stock Analysis: Viatris
Via Talk Markets
Better Pharma Buy: Viatris vs. Pfizer
Via The Motley Fool
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Via Benzinga
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
Via Benzinga
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Via The Motley Fool
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
Via The Motley Fool
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Better High-Yield Dividend Stock: Altria or Viatris?
Via The Motley Fool
VTRS DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.